Macrocyclic compounds for suppressing replication of hepatitis c virus

A compound of Formula (I) or a pharmaceutically acceptable salt thereof:

• wherein,
• R1 is —CO2Ra, —CONRbSO2Rc, —CONRdSO2NReRf, or tetrazolyl;
• R2 is C1-C6 alkyl, C2-C6 alkenyl, or C3-C8 cycloalkyl, and said groups each are optionally substituted with 1-3 halo;
• R3 is C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkyl substituted with C3-C8 cycloalkyl, or C1-C8 alkyl or heteroalkyl substituted with aryl, and said groups each are optionally substituted with 1-3 halo;
• R4 is H, C1-C6 alkyl, —SO2Rc, —SO2NRdRe, —CONRfRg, —COORh, or —CORi;
• n is 1 or 2;
• p is 0, 1 or 2;
• M is —O—, —S— or —NH—;
• L is C1-C6 alkylene, C2-C6 alkenyl, or C2-C6 alkynyl;
• W is halo, hydroxyl, NO2, CN, CF3, OCF3, —NRaRb, —SO2Rc, —SRc, —SO2NRdRe, —CONRfRg, —COORh, —NRiCORj, —NRkSO2Rl, C1-C6 alkyl, —O—C1-C6 alkyl, C3-C7 cycloalkyl, aryl, or heteroaryl;
• Z is C1-C6 alkylene, —O—, —O—C1-C5 alkylene, —C(O)O—, C1-C5 alkylene-C(O)O—, —C(O)NRaRb—, or C1-C5 alkylene-C(O)NRaRb—;
• ring A is a 8-14 membered fused bicyclic or tricyclic carbon structure, optionally substituted with 1-4 N, O, or S heteroatoms;
• each Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rl is independently H, C1-C6 alkyl, C3-C7 cycloalkyl, C5-C10 aryl or heteroaryl, or C1-C6 alkylene C5-C10 aryl or heteroaryl.